Company intelligence / Profile preview

Amylin Pharmaceuticals

San Diego, California, United Statesamylin.com ↗
Ownership
Private
Employees
~535
Development stage
Other
01

Overview

Amylin Pharmaceuticals developed and commercialized several first-in-class therapies for diabetes and metabolic disorders. Its lead products included pramlintide (Symlin) and exenatide-based drugs (Byetta and Bydureon). These drugs were approved for the treatment of type 2 diabetes; Symlin was also approved for type 1 diabetes as an adjunct to insulin. Byetta was the first GLP‑1 agonist approved in the US. At acquisition in 2012 by Bristol Myers Squibb (and subsequently AstraZeneca), these products were on market with established efficacy in glycemic control.

Therapeutic areas
Metabolic DisordersEndocrinology
Modalities
Small moleculePeptidesProtein
Industry
Biotech
02

Partnerships

Eli Lilly & Co. (historic development/commercialization partnership on exenatide)Johnson & Johnson/LifeScan division partnership on pramlintide developmentBristol Myers Squibb/AstraZeneca alliance post-acquisition

Beyond the preview

Go deeper on Amylin Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amylin Pharmaceuticals.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call